Xbrane Biopharma AB stock analysis
Xbrane Biopharma AB (7XB0) Stock Price & Analysis
7XB0 Stock Chart & Stats
- Day’s Range
- EUR 0.95 - EUR 0.98
- 52-Week Range
- EUR 0.45 - EUR 1.55
- Previous Close
- EUR 1.01
- Volume
- N/A
- Average Volume (3M)
- 64
- Market Cap
- EUR 21.25M
- Enterprise Value
- EUR 253.18M
- Total Cash (Recent Filing)
- EUR 37.41M
- Total Debt (Recent Filing)
- EUR 63.93M
- Price to Earnings (P/E)
- ―
- Beta
- 1.14
- Next Earnings
- Feb 19, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong TTM Revenue Growth
TTM revenue growth of 53.6% indicates meaningful commercial expansion and increasing demand for the company’s offerings. If growth can persist, it may improve operating leverage, support investment in the development pipeline, and strengthen the platform’s ability to reach sustainable scale.
Manageable Current Leverage
Low current debt relative to equity provides financial flexibility while the company funds development and commercialization activities. This comparatively manageable leverage profile can reduce near-term balance-sheet pressure and preserve capacity to respond to operating needs or pursue growth.
Focused Biosimilar Business Model
A focus on biosimilars targets lower-cost alternatives to established biologic medicines across immunology and oncology. The integrated model spans development, clinical work, and regulatory activities, creating a durable platform for building and commercializing follow-on biologic products.
Bears Say
Persistent Net Losses
The sizable TTM net loss and deeply negative operating margins show that revenue growth has not yet translated into sustainable profitability. Continued losses can constrain reinvestment, weaken financial resilience, and make future earnings dependent on successful commercialization and improved operating economics.
Significant Cash Burn
Materially negative operating and free cash flow indicates that the business is consuming cash rather than funding operations internally. Declining free cash flow increases reliance on external funding and can restrict the company’s ability to advance its pipeline without additional financing.
Volatile Capital Structure
Although leverage is currently low, the history of materially higher leverage shows that the capital structure has been volatile during periods of operating losses. This creates a longer-term financial risk because renewed cash needs could again pressure funding flexibility and shareholder returns.
Xbrane Biopharma AB News
Xbrane Reaches Key Milestone as Xdivane Pivotal Trial Fully Enrolls Melanoma Patients
Xbrane Biopharma AB ( ($SE:XBRANE) ) has shared an announcement. Xbrane Biopharma AB and its strategic partner Intas Pharmaceuticals have completed patient recruitment for the pivotal clinical trial of Xdivane™,
7XB0 FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
What is Xbrane Biopharma AB’s market cap?
When is Xbrane Biopharma AB’s upcoming earnings report date?
How were Xbrane Biopharma AB’s earnings last quarter?
Is Xbrane Biopharma AB overvalued?
Does Xbrane Biopharma AB pay dividends?
What is Xbrane Biopharma AB’s EPS estimate?
How many shares outstanding does Xbrane Biopharma AB have?
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin Amark
- Employees
- 28
- Website
- www.xbrane.com
- Address
- Scheeles väg 5, Solna, AB, 171 65, SE
Xbrane Biopharma AB (7XB0) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 1 | 12 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 3 | 0 | 9 |









